Analogic Corporation Receives Additional Orders for Its EXplosive Assessment Computed Tomography -EXACT- Systems.

Business Editors/High-Tech Writers

PEABODY, Mass.--(BUSINESS WIRE)--Dec. 5, 2002

-Bernard M. Gordon, Chairman of the Board and CEO of Analogic Corporation (NASDAQ: ALOG), announced today that the Company has received additional orders for its EXplosive Assessment Computed Tomography (EXACT(TM)) Systems from L-3 Communications' (NYSE: LLL) Security and Detection Systems division. The EXACT is the "heart" of L-3's eXaminer 3DX(TM) 6000, a certified Explosive Detection System (EDS) that is being purchased by the U.S. Transportation Security Administration (TSA) to be installed at major airports across the U.S.

The order from L-3 calls for the delivery of an additional 75 EXACT units for foreign and other anticipated orders. These units will be delivered at a rate of approximately eighteen to twenty systems per month during the first four months of calendar 2003.

Earlier this year Analogic had received in accord with a blanket order for 1000 systems, firm orders for 425 systems for delivery by calendar yearend. The Company is on schedule to deliver these units on or before December 31, 2002.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing.

This press release contains the Company's or management's intentions, hopes, beliefs, expectations or predictions. These are considered "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements (statements which are not historical facts) in this presentation are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements, including statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development expenses and trends, and capital expenditures involve risk and uncertainties and actual events and results may differ significantly from those in any forward-looking statements. Actual results may differ materially from those indicated by such statements as a result of various factors, including those discussed in the Company's periodic reports filed with the SEC.